The question “what cholesterol level is normal?” does not have a universal answer.
In clinical practice, lipid assessment is always individualized and based on the patient’s overall cardiovascular risk.
Cardiovascular risk assessment
There is a concept of cardiovascular risk, according to which patients are classified into groups:
- very high risk
- high risk
- moderate risk
- low risk
Risk assessment is not a one-time process — it is evaluated dynamically, as it depends on multiple factors, including age, blood pressure, sex, smoking status, medications, region of residence, and the presence of comorbidities (diabetes mellitus, prior myocardial infarction, stroke, chronic kidney disease, etc.).
LDL-C target levels
Target levels of low-density lipoprotein cholesterol (LDL-C) depend on the risk category:
- very high risk — less than 1.4 mmol/L (55 mg/dL)
- high risk — less than 1.8 mmol/L (70 mg/dL)
- moderate risk — less than 2.5 mmol/L (100 mg/dL)
- low risk — less than 3.0 mmol/L (116 mg/dL)
Thus, the concept of a “normal” cholesterol level is relative and depends on individual risk.
“Gray zones” and clinical decisions
There are situations where decisions about lipid-lowering therapy are made individually. For example, in a young patient without risk factors (hypertension, obesity, smoking), an LDL-C level slightly above 3.0 mmol/L may not require immediate pharmacological treatment. At the same time, an LDL-C level ≥4.9 mmol/L is considered suggestive of familial hypercholesterolemia and requires treatment initiation. Total cholesterol is mainly used as a general reference and is not the primary decision-making parameter. Triglycerides are assessed separately and have their own clinical considerations.
Lipoprotein(a) — a new standard in risk assessment
Modern guidelines include mandatory assessment of lipoprotein(a) [Lp(a)]. Lipoprotein(a) is a specific cholesterol particle bound to a protein and is an independent, genetically determined risk factor for atherosclerosis, coronary artery disease, myocardial infarction, and stroke.
Lp(a) levels:
- are genetically determined
- do not depend on lifestyle or most therapies
Therefore, it is recommended to measure it at least once in a lifetime. Elevated Lp(a) may change cardiovascular risk category and influence treatment strategy, including the need for more intensive lipid-lowering therapy.
Apolipoprotein B (ApoB)
In addition to the standard lipid panel, guidelines also include apolipoprotein B (ApoB). ApoB is a carrier protein of atherogenic lipoproteins and reflects the total number of “atherogenic particles.” Unlike Lp(a), ApoB levels can change and are used for monitoring therapy. For example, if LDL-C targets are reached but ApoB remains elevated, intensification of therapy may be needed.
When and how often to check lipids
Lipid screening is performed at different ages. Previously, screening started after age 35 in men and 40 in women, but current approaches recommend earlier evaluation.
Children:
- under 2 years — only if risk factors or suspected familial hypercholesterolemia
- 9–11 years — universal screening
Adults:
- initial assessment — around 18–20 years
- low risk — every 5 years
With risk factors:
- more frequent monitoring, usually once a year
During treatment:
- 4–12 weeks after initiation or change
- then every 6–12 months
Lipid assessment is not a one-time test, but a continuous process of monitoring and managing cardiovascular risk. An individualized approach and regular follow-up are key to early detection and prevention of cardiovascular disease.